Milestone Scientific Schedules Second Quarter 2019 Conference Call

Milestone Scientific, Inc.

Companies Mentioned:

Primary Exchange: AMEX
Under the Symbol: MLSS

$1.51

($0.0300)

-1.9481


Milestone Scientific Schedules Second Quarter 2019 Conference Call

Monday, August 12, 2019 8:00 AM

LIVINGSTON, NJ / ACCESSWIRE / August 12, 2019 / Milestone Scientific Inc. (NYSE American:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it will host a conference call at 8:30 AM Eastern Time on Friday, August 16, 2019 to discuss the Company’s financial results for the second quarter ended June 30, 2019, as well as the Company’s corporate progress and other developments.

The conference call will be available on the Company’s website at www.milestonescientific.com, or via telephone by dialing toll free 888-394-8218 and entering the pass code: 7780393. For those unable to participate at that time, a replay of the call will be archived on the company’s website or can be accessed by dialing 888-203-1112 and entering the pass code 7780393. The replay will be available for 90 days.

About Milestone Scientific Inc.

Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs, develops and commercializes innovative diagnostic and therapeutic injection technologies and instruments for medical, dental, cosmetic and veterinary applications. Milestone's computer-controlled systems are designed to make injections precise, efficient, and virtually painless. Milestone’s proprietary DPS Dynamic Pressure Sensing technology® is our technology platform that advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for cosmetic botulinum toxin injections, epidural space identification in regional anesthesia procedures and intra-articular joint injections. For more information please visit our website: www.milestonescientific.com.

Contact:

David Waldman or Natalya Rudman
Crescendo Communications, LLC

Email: [email protected]
Tel: 212-671-1020

SOURCE: Milestone Scientific, Inc.


Subscribe to alerts from Investor Network
SHARE ARTICLE